In response to this Q:

https://twitter.com/felbalazard/status/1355930788160811014?s=20

I give a list of activities that were kicked off by the ICH E9 estimands addendum (I believe) and that I am aware of (and/or involved in). I am sure there is much more, so no ambition at all to be comprehensive.

Please RT!

1) NPH: https://arxiv.org/abs/1908.07112  (and several more papers, e.g. on max-combo tests).

2) Special interests groups:

oncology: http://www.oncoestimand.org  (PSI / EFSPI and ASA biopharmaceutical section), browse events and publications

neuroscience: https://psiweb.org/sigs-special-interest-groups/neuroscience-estimands.

EFPIA / PSI on estimands implementation (I am not sure they have a webpage already)

3) Many events, see e.g.

http://bbs.ceb-institute.org/ 

https://www.psiweb.org/events/event-item/2020/11/05/default-calendar/joint-psi-efspi-asa-biop-webinar-estimands

https://oncoestimand.github.io/oncowg_webpage/conferences.html

https://www.efpia.eu/news-events/events/efpia-event/psi-eiwg-webinar-pioneering-estimands-in-clinical-research/ https://www.cytel.com/webinar-replay-estimands-in-oncology

4) The onco estimand WG has several papers on various topics around implementation, see https://oncoestimand.github.io/oncowg_webpage/oncoestimand.html#publications

Topics:
- Treatment switching.
- Solid tumors.
- Hematology.
- PRO,
- Application of principal stratification strategy (with a gentle intro to causal inference).

5) Many more topics are worked on around academia, industry, and regulators. E.g., the onco estimand WG kicked off task forces for:

1) Clinical engagement
2) Principal stratum application for tmt switching
3) PRO
4) Time to Response and DOR
5) Follow-up for Quantification

6) Estimands and RWD
7) Conditional vs Marginal
8) Time-to-event endpoints with prognostic or predictive biomarker subgroups

As said, by no means comprehensive. Please reach out if you'd like more info. And please RT!

@threadreaderapp unroll